Article thumbnail

Paliperidone ER in the Treatment of Borderline Personality Disorder: A Pilot Study of Efficacy and Tolerability

By Silvio Bellino, Paola Bozzatello, Camilla Rinaldi and Filippo Bogetto


Antipsychotics are recommended for the treatment of impulsive dyscontrol and cognitive perceptual symptoms of borderline personality disorder (BPD). Three reports supported the efficacy of oral risperidone on BPD psychopathology. Paliperidone ER is the metabolite of risperidone with a similar mechanism of action, and its osmotic release reduces plasmatic fluctuations and antidopaminergic effects. The aim of this study is to evaluate efficacy and safety of paliperidone ER in BPD patients. 18 outpatients with a DSM-IV-TR diagnosis of BPD were treated for 12 weeks with paliperidone ER (3–6 mg/day). They were assessed at baseline, week 4, and week 12, using the CGI-Severity item, the BPRS, the HDRS, the HARS, the SOFAS, the BPD Severity Index (BPDSI), and the Barratt Impulsiveness Scale (BIS-11). Adverse events were evaluated with the DOTES. Paliperidone ER was shown to be effective and well tolerated in reducing severity of global symptomatology and specific BPD symptoms, such as impulsive dyscontrol, anger, and cognitive-perceptual disturbances. Results need to be replicated in controlled trials

Topics: Research Article
Publisher: Hindawi Publishing Corporation
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (2010). A comparison of serum prolactin concentrations after administration of paliperidone extended-release and risperidone tablets in patientswithschizophrenia,”JournalofPsychopharmacology,vol.
  2. (2004). A preliminary, randomized trial of fluoxetine, olanzapine, and the olanzapine-fluoxetine combination in women with borderline personality disorder,”
  3. (1960). A rating scale for depression,”
  4. (2005). Absorbtion, metabolism and excretion of a single oral dose of 14C-paliperidone 1mg in healthy subjects,”
  5. (2001). American Psychiatric Association, Practice Guidelines for the Treatment of Patients with Borderline Personality Disorder, American Psychiatric Association,
  6. (1997). and L.S.Benjamin,StructuredClinicalInterviewforDSM-IVdisorders Axis II
  7. (2004). Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management,”
  8. (2006). Aripiprazole in the treatment of patients with borderline personality disorder: a double-blind, placebo-controlled study,”
  9. (2006). Aripiprazole pharmacotherapy of borderline personalitydisorder:aseriesofthreeconsecutivecasereports,”
  10. (2007). Aripiprazole treatment of patients with borderline personality disorder,”
  11. Association, Diagnostic and Statistical Manual of Mental Disorders, American Psychiatric Association,
  12. (2008). Atypical antipsychotic-induced metabolic sideeffects:insightsfromreceptor-bindingprofiles,”Molecular Psychiatry,
  13. (2010). C.A.HarringtonandC.English,“Tolerabilityofpaliperidone: ameta-analysisofrandomized,controlledtrials,”International Clinical Psychopharmacology,
  14. (2004). C.U.Correll,S.Leucht,andJ.M.Kane,“Lowerriskfortardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies,”
  15. (2005). Campins et al., “Double-blind, placebo-controlled study of dialectical behavior therapy plus olanzapine for borderline personality disorder,”
  16. Clinical global impression (C.G.I.),”
  17. (2006). Clinical spectrum of the osmotic-controlled release oral delivery system (OROS), an advanced oral deliveryform,”CurrentMedicalResearchand Opinion,
  18. (2002). Clinical use of quetiapine in disease states other than schizophrenia,”
  19. (2002). Clozapine and borderline personality disorder,” Psychiatric Services,
  20. (1993). Clozapine treatment of borderline patients: a preliminary study,”
  21. (2001). Comparison of the effects of clozapine, chlorpromazine, and haloperidol on membrane lateral heterogeneity,”
  22. (2003). De Bie, “Reliability and validity of the borderline personality disorder severity index,”
  23. (1976). Dosage Record and Treatment Emergent Symptoms scale (DOTES),” in ECDEU Assessment Manual for Psychopharmacology—Revised,
  24. (2007). Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study,”
  25. (2008). Efficacy and tolerability of aripiprazole augmentation in sertraline-resistant patients with borderline personality disorder,”
  26. (2008). Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies,”
  27. (2006). Efficacy and tolerability of quetiapine in the treatment of borderline personality disorder: a pilot study,”
  28. (2007). Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebocontrolled study,”
  29. (2009). Expected clinical benefits of paliperidone extended-release formulation when compared with risperidone immediate-release,”
  30. (2008). F r i e d e l ,W .T .J a c k s o n ,C .S .H u s t o n
  31. (1965). Factor analysis of some psychometric measures of impulsiveness and anxiety,”
  32. (2005). Guideline Watch: Practice Guideline for the Treatment of Patients with Borderline Personality Disorder, American Psychiatric Association,
  33. (2008). Hyperprolactinemia and prolactinomas,”
  34. (1994). Impulsiveness and aggression,” in Violence and Mental Disorder: Developments in Risk Assessment,
  35. (2008). Long-acting injectable risperidone in treatment resistant borderline personality disorder. A small series report,”
  36. (1998). Low-dose clozapine in acute and continuation treatment of severe borderline personality disorder,”
  37. (1999). M e l t z e ra n dS .R .M c G u r k ,“ T h ee ffects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia,”
  38. (2005). n e g t e r i n g ,P .B a s e l m a n s ,S .C a s t e l e i n ,F .B o s k e r
  39. (2008). Naudts et al., “Efficacy of quetiapine for impulsivity and affective symptoms in borderlinepersonalitydisorder,”JournalofClinicalPsychopharmacology,
  40. (1999). Olanzapine safety and efficacy in patients with borderline personality disorder and comorbid dysthymia,”
  41. (2001). Olanzapine treatment of female borderline personality disorder patients: a doubleblind, placebo-controlled pilot study,”
  42. (2004). Olanzapine versus placebo in the treatment of borderline personality disorder,”
  43. (2005). Open-label study of atypical neuroleptic quetiapine for treatment of borderline personality disorder: impulsivity as main target,”
  44. (2002). P.Rocca,L.Marchiaro,E.Cocuzza,andF.Bogetto,“Treatment ofborderlinepersonalitydisorderwithrisperidone,”Journalof Clinical Psychiatry,
  45. (2009). Paliperidone extended-release for schizophrenia: effects on symptoms and functioning in acutely ill patients with negative symptoms,”
  46. (2008). Paliperidone extended-release for the treatment of schizophrenia,”
  47. Paliperidone for schizophrenia,”
  48. (2008). Paliperidone-ER: first atypicalantipsychoticwithoralextendedreleaseformulation,”
  49. (2005). Pharmacokinetic and dopamine D2 and serotonin 5-HT2A receptor occupancy of paliperidone in healthy subjects,”
  50. (2006). Pharmacokinetics, dopamine D2 and serotonin 5-HT2A receptor occupancy and safety profile of paliperidone extended-release in healthy subjects,”
  51. (2006). Prolactin elevation of the antipsychotic risperidone is predominantly related to its 9-hydroxy metabolite,”
  52. (2001). Psychometric propertiesofanItalianversionoftheBarratImpulsiveness Scale-11 (BIS-11) in nonclinical subjects,”
  53. (2007). Quetiapine for the treatment of borderline personality disorder; an open-label study,”
  54. (2008). Quetiapine in patients with borderline personality disorder:anopen-labeltrial,”AnnalsofClinicalPsychiatry,vol.
  55. (2003). Quetiapine in the treatment of borderline personality disorder,”
  56. (2009). Quetiapine treatment and improved cognitive functioning in borderline personality disorder,”
  57. (2000). Receptor profile of antipsychotics,” in Atypical Antipsychotics,B .A .E l l e n b r o e ka n dA
  58. (1992). Revising axis V for DSM-IV: a review of measures of social functioning,”
  59. (1996). Risperidone comparedwithnewandreferenceantipsychoticdrugs:invitro and in vivo receptor binding,”
  60. (1997). Risperidone in comorbid borderline personality disorder and dysthymia,”
  61. (2008). Safety and tolerability of oral paliperidone extended-release tablets in elderly patients with schizophrenia: a double-blind, placebocontrolled study with six-month open-label extension,”
  62. (1994). Schotte et al., “Survey on the pharmacodynamics of the new antipsychotic risperidone,”
  63. (2007). The pharmacology and safety of paliperidone extended-release in the treatment of schizophrenia,”
  64. (1993). Training and quality assurance with the Brief Psychiatry Rating Scale: “the drift busters”,”
  65. (2007). Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial,”
  66. (2004). Ziprasidone in the acute treatment of borderline personality disorder in psychiatric emergency services,”